1[5]Dagher L, Patch D, Marley R, et al. Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther ,2000,14(5):515-521.
2[6]Hadengue A, Godano A, Moreau R, et al. Benefical effects of the z-day administraction of terlipression in patients with cirrhosis and hepatorenal syndrome. J hepatol, 1998,29(4):565-570.
3[7]Kaffy F, Borderie C, Chagneau C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhostic patients. J Hepatol, 1999, 30(1):174.
4[8]Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha - adrenergic agonist, on renal hemodynamic and renal function in cirrhotic patients with ascites. Hepatology,1998,28(4):937-943.
5[9]Roberts LR, Kamath PS. Ascites and hepatorenal syndrome: Pathophysiology and management. Mayo Clin Proc, 1996,71(9):874-881.
6[10]Brensing KA, Textor J, Strunk H, et al. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet, 1997, 349(9053):697-698.
7[11]Gentilini P. Hepatorenal syndrome and ascites: A introduction. Liver,1999,19(1suppl):5-14.
8[12]Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplantation renal function on survival after liver transplantation. Transplantation, 1995,59(3):361-365.
9[1]Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology, 1996,23:164-176.
10[2]Eckardt KU. Renal failure in liver disease. Intensive Care Med, 1999,25(1):5-14.
4Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome : results of a prospective, nonrandomized study. Hepatology ,2002,36 ( Pt1) :941 - 948.
5Wong F, Blendis L. New challenge of hepatorenal syndrome : prevention and treatment. Hepatology, 2001,34 (6) : 1242 - 1251.
6Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology ,2004 ,40:55 - 64.
7Pomier - Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double - blind, placebo - controlled, crossover study. Hepatology ,2003,38:238 - 243.
8Capling RK,Bastani B. The clinical course of patients with type Ⅰ hepatorenal syndrome maintained on hemodialysis. Ren Fail, 2004,26 ( 5 ) : 563 - 568.
9Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute - on - chronic liver failure: a randomized controlled study. Liver Transpl, 2004,10 ( 9 ) : 1109 - 1119.
10Testino G,Ferro C ,Sumberaz A ,et al. Type- 2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent - shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Gastroenterol Hepatol,2003,50(54):1753 - 1755.
